Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Comment: CDK4/6 inhibitors in advanced breast cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 29.09.19
Views: 796
Rating:

Prof Nadia Harbeck - University of Munich, Munich, Germany

Prof Nadia Harbeck comments on data from two studies looking at CDK4/6 inhibitors in advanced breast cancer during a press conference at the 2019 ESMO congress.

The MONALEESA-3 trial was looking at treatment with the CDK4/6 inhibitor ribociclib plus fulvestrant in postmenopausal patients and the MONARCH 2 trial looked at the CDK4/6 inhibitor abemaciclib plus fulvestrant in pre-, and peri- and postmenopausal breast cancer patients.

Watch the press conference about the MONALEESA-3 trial here.

Watch the press conference about the MONARCH 2 trial here

Watch Prof George Sledge's interview with ecancer here

Watch Prof Dennis Slamon's interview with ecancer here

Read more about the studies here

Related videos

follow us

Biosimilar Medicines Core Principles and Communication


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation